Pharmacogenomics and Targeted Therapy in Patient Care as presented by Wolfgang Sadee, Dr.rer.nat;
Felts Mercer Professor of Medicine and Pharmacology, The Ohio State University;
Director, Pharmacogenomics Program, The Ohio State University Medical Center
7. CYP3A4 expression in human livers Gen.Eng.News 21:29 (2001) Epidauros Biotechnologie. Bernried, Germany Genetic and/or environmental causes for CYP3A4 variability ?? CYP2D6 test comprehensive?? Do current PGx test account for all/most Genetic causes of variability ?
8. CYP3A4 Intronic SNP (4-8% allele frequency) affects expression 2-5 fold Decreases statin dose requirements Wang et al. TPJ 2010 singleton : does not tag anything (positive selection?) Missed by GWAS
11. DRD2 splice variants: interaction with cocaine rs2283265 association with cocaine abuse P=0.001, OR 3.33 (1.42-7.80) (n=~200) Moyer et al. (submitted) Gene-gene interactions (epistasis): DRD2 – DAT Dopamine Transporter Possibly 3 functional variants Impact on mRNA expression in SN DRD2 – DAT in cocaine abuse: DAT SNPs protective Association with bipolar disorder OR ~2 Pinsonneault et al., to be submitted
12.
13.
14. Sadee/PGx Lab: Ryan Smith Leslie Newman Collaborators: Julie Johnson Danxin Wang Audrey Papp Danielle Sullivan Phil Binkley David Saffen Julia Pinsonneault Beth Barrie Gloria Smith Anil Malhotra Anke Hilse van der Zee Robert Moyer Jonathan Sanford Andrew Johnson Deborah Mash Alessandro Bertolino
Editor's Notes
Billions of reads of short sequence. But, what are we sequencing, and what can we expect from the results?
![[object Object],[object Object],[object Object],[object Object],Why do we need genetic biomarkers in drug therapy?](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)